According to the MultipleMyelomaHub CT103A is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) which is found on the surface of myeloma plasma cells. It contains a fully-human BCMA antibody, designed to reduce the toxic side effects often induced by non-human constructs.
References provided by the MultipleMyelomaHub on its website:
- Business Wire. NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Biologics.https://www.businesswire.com/news/home/20191002005214/en[Accessed 2019 Oct 10]
- Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma.https://myelomaresearchnews.com/2019/10/09/ct103a-cleared-clinical-studies-relapsed-refractory-mm-in-china/[Accessed 2019 Oct 10]
- Chinese Clinical Trial Registry. An open-label, single-center and single-arm clinical study of infusion of anti-BCMA CAR-T cells for patients with relapsed or refractory plasma cell malignancies.http://www.chictr.org.cn/showprojen.aspx?proj=30653 [Accessed 2019 Oct 10]
- Wang J.et al., Clinical Responses and Pharmacokinetics of fully-human BCMA targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. XVII International Myeloma Workshop (IMW). 2019 Sep 14. Abstract #OAB-033